ロード中...
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313
In the S0313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus involved field radiotherapy (IFRT) in patients with limited-stage aggressive B-cell non-Hodgkin lymphom...
保存先:
| 出版年: | Blood |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4287635/ https://ncbi.nlm.nih.gov/pubmed/25395425 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-584623 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|